HER2 therapy: Molecular mechanisms of trastuzumab resistance

trastuzumab A drug used alone or with other drugs to treat certain types of breast cancer, stomach cancer, and gastroesophageal junction cancer that are HER2

Trastuzumab, a humanized monoclonal antibody against the ectodomain of HER2 Trastuzumab uses multiple mechanisms to interfere with HER2 downstream

trastuzumab Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast

trastuzumab Key Message The ShortHER trial failed to demonstrate the non-inferiority of 9 weeks versus 1 year of adjuvant trastuzumab combined with chemotherapy The short